Current and emerging prognostic factors for MDS/MPN

preview_player
Показать описание
Eric Solary, MD, Gustave Roussy Institute, Paris, France, outlines currently used prognostic factors for myelodysplastic/myeloproliferative neoplasms (MDS/MPN), highlighting the need to include novel markers to better predict patient outcomes, including flow cytometry analysis of peripheral blood (PB) cells and inflammatory cytokine levels in the blood and bone marrow. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Eric Solary
  3. Institution: Gustave Roussy Institute
  4. Event: MDS 2023
  5. Format: Interview
  6. Subject: Myelodysplastic Syndromes
Рекомендации по теме
Current and emerging 0:01:26

Current and emerging prognostic factors for MDS/MPN

Prognostic Factors and 0:08:33

Prognostic Factors and the Impact of New Therapies

Long-term outcomes and 0:11:47

Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis

Diagnosis, Prognosis, and 0:18:09

Diagnosis, Prognosis, and Therapy of True ET vs. Prefibrotic MF

Developments in prognostic 0:01:42

Developments in prognostic factors of acute myeloid leukemia (AML)

Prognostic Factors in 0:05:02

Prognostic Factors in Patients With CLL

Special Focus Dialogue 0:58:55

Special Focus Dialogue – Prognosis in Cancer: staging, prognostic factors, outcomes

TNBC Current and 1:08:58

TNBC Current and Emerging Therapeutic Strategies | 2023 Best of Breast Conference

Impact of Prognostic 0:06:00

Impact of Prognostic Factors on Clinical Decisions in CLL

Prognostication and initiation 0:19:02

Prognostication and initiation of therapy in Polycythemia vera: Do we have it right?

New Biomarkers and 0:10:24

New Biomarkers and Prognostic Indicators in Leukemia and MDS

Daniel Pollyea, MD, 0:01:26

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

Prognostic Stratification by 0:15:35

Prognostic Stratification by Phenotypic Subtypes Emerging from Diverse Evolutionary Paths in HCC

Prognosis and outcome 0:20:50

Prognosis and outcome of patients with advanced ET and PV

An introduction to 0:31:33

An introduction to risk prediction and prognostic models

Episode 69 Digitally 0:17:34

Episode 69 Digitally quantitated tumor cellularity as a prognostic factor in NSCLC

Prognostic Factors and 0:35:23

Prognostic Factors and Outcomes in Minor Salivary Gland Carcinoma (MSGC) (Graphic)

Diagnosis, Staging, and 0:10:09

Diagnosis, Staging, and Prognosis

Oncology Clinical Trials: 0:17:28

Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design

Diagnosis, Staging, and 0:10:09

Diagnosis, Staging, and Prognosis

Updates on AL 0:32:34

Updates on AL Amyloidosis Treatment: What is New in 2022: Giada Bianchi, MD

Incorporating Prognostic Factors 0:04:10

Incorporating Prognostic Factors in Melanoma

REDLAMP 9: Prognostic 0:06:11

REDLAMP 9: Prognostic Factors for Clinical Outcomes in Patients with Plasmablastic Lymphoma

Established and Emerging 0:56:42

Established and Emerging Prognostic Markers in Prostate Pathology